Pregled bibliografske jedinice broj: 1112620
A computational insight into the mechanism of the irreversible inhibition of monoamine oxidase enzymes by the antiparkinsonian propargylamine inhibitors rasagiline and selegiline
A computational insight into the mechanism of the irreversible inhibition of monoamine oxidase enzymes by the antiparkinsonian propargylamine inhibitors rasagiline and selegiline // 18th Hellenic Symposium on Medicinal Chemistry : Abstract Book
online, 2021. 133, 1 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1112620 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
A computational insight into the mechanism of the
irreversible inhibition of monoamine oxidase
enzymes by the antiparkinsonian propargylamine
inhibitors rasagiline and selegiline
Autori
Tandarić, Tana ; Vianello, Robert
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
18th Hellenic Symposium on Medicinal Chemistry : Abstract Book
/ - , 2021
Skup
18th Hellenic Symposium on Medicinal Chemistry (HSMC 2021)
Mjesto i datum
Online, 15.02.2021. - 27.02.2021
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
monoamine oxidases
Sažetak
Monoamine oxidases (MAOs) are flavoenzymes that catalyze the degradation of a range of brain neurotransmitters, whose imbalance is extensively linked with the pathology of various neurological disorders. This is why MAOs have been the central pharmacological targets in treating neurodegeneration for more than 60 years. Still, despite this practical importance, the precise chemical mechanisms underlying the irreversible inhibition of the MAO B isoform with clinical drugs rasagiline (RAS) and selegiline (SEL) remained unknown. We employed a combination of MD simulations, MM- GBSA binding free energy evaluations, QM cluster calculations[1] and EVB simulations[2] to show that the MAO inactivation proceeds in three steps, where, in the rate- limiting first step, FAD utilizes its N5 atom to abstracts a hydride anion from the inhibitor α-CH2 group to ultimately give the final inhibitor-FAD adduct matching crystallographic data. The obtained free energy profiles reveal a lower activation energy for SEL by 3.1 kcal mol–1, being in excellent agreement with experimental ΔΔG‡EXP = 1.7 kcal mol–1, thus rationalizing its higher in vivo reactivity over RAS and supporting the validity of the proposed mechanism. The calculated ΔGBIND energies confirm SEL binds better due to its bigger size and flexibility allowing it to optimize the hydrophobic C–H•••π and π•••π interactions with residues throughout both of enzyme's cavities, particularly with FAD, Gln206 and four active site tyrosines, thus overcoming a larger ability of RAS to form hydrogen bonds that only position it in less reactive orientations for the hydride abstraction. Accordingly, desmethyl- SEL turned out to be the least effective inhibitor, while the N- methyl analogue of RAS is identified as the most potent compounds, and its further experimental characterization is strongly recommended. Offered results elucidate structural determinants affecting the affinity and rates of the inhibition reaction that should be considered to cooperate when designing more effective compounds devoid of untoward effects, which are of utmost significance and urgency with the growing prevalence of brain diseases.
Izvorni jezik
Engleski
Znanstvena područja
Kemija
POVEZANOST RADA
Projekti:
EK-KK.01.1.1.04.0013 - Inovativna rješenja u katalitičkim proizvodnim procesima za potrebe farmaceutske industrije (CAT PHARMA) (Kirin, Srećko, EK ) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb